A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

New research suggests that a breast cancer vaccine developed decades ago may have triggered a lasting immune memory response that can now be significantly boosted by a newly developed antibody.

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Early research suggests the immune system may one day be trained to prevent cancer in people with inherited risk.

He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...

Moderna and Merck's melanoma vaccine, combined with Keytruda, could halve cancer recurrence risk, marking a breakthrough in ...

NORTON, Zimbabwe (AP) — Lesotho’s Lishoeshoe soccer club was losing by four goals at halftime against South Africa’s Mamelodi ...